A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis (ORARIALS)

Diagnosis ALS
Study phase Recruiting
Participating centres UMC Utrecht

A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS).

Overall enrolment: 231 patients

Centres: 11 sites in the US, 2 sites in Canada, 1 site in Belgium, 2 sites in France, 2 sites in Italy, 2 sites in Spain, 1 site in Sweden, 1 site in The Netherlands (UMCU)

READ MORE ON CLINICALTRIALSREGISTER.EU READ MORE ON CLINICALTRIALS.GOV